RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫细胞对癌症特征的影响：一项文献综述
英文原题：Impact of immune cells on the hallmarks of cancer: A literature review.
查看英文原题
Impact of immune cells on the hallmarks of cancer: A literature review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤浸润免疫细胞（TIICs）在肿瘤微环境中起关键作用，调节癌细胞功能。TIICs具有高度异质性和可塑性，可能抑制癌症或支持肿瘤生长。大量研究揭示了肿瘤相关巨噬细胞、树突状细胞、中性粒细胞、肥大细胞、NK 细胞和淋巴细胞如何促进癌症多个标志性特征的建立，并成为成功免疫治疗的基础。其中许多TIICs在癌症的多个标志性特征中发挥关键作用。本综述有助于阐明免疫细胞在癌症发展中的多方面作用，重点介绍构成有前景治疗靶点的分子组分。需要进一步研究以阐明TIICs与诸如实现复制性永生化、逃避生长抑制因子、维持增殖信号、抵抗细胞死亡以及基因组不稳定和突变等标志性特征之间的关系，以进一步探索其治疗潜力并改善癌症患者的预后。
展开英文摘要原文
Tumor-infiltrating immune cells (TIICs) are critical players in the tumor microenvironment, modulating cancer cell functions. TIICs are highly heterogenic and plastic and may either suppress cancers or provide support for tumor growth. A wide range of studies have shed light on how tumor-associated macrophages, dendritic cells, neutrophils, mast cells, natural killer cells and lymphocytes contribute for the establishment of several hallmarks of cancer and became the basis for successful immunotherapies. Many of those TIICs play pivotal roles in several hallmarks of cancer.
This review contributes to elucidate the multifaceted roles of immune cells in cancer development, highlighting molecular components that constitute promising therapeutic targets. Additional studies are needed to clarify the relation between TIICs and hallmarks such as enabling replicative immortality, evading growth suppressors, sustaining proliferative signaling, resisting cell death and genome instability and mutation, to further explore their therapeutic potential and improve the outcomes of cancer patients.
论文信息
- 作者
- Costa AC、Santos JMO、Gil da Costa RM、Medeiros R
- 第一作者单位
- Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal; Faculty of Medicine of the University of Porto (FMUP), 4200-319, Porto, Portugal. Electronic address: alexandra.costa@ipoporto.min-saude.pt.Portugal
- 通讯作者单位
- Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal; Faculty of Medicine of the University of Porto (FMUP), 4200-319, Porto, Portugal; Virology Service, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072, Porto, Portugal; CEBIMED, Faculty of Health Sciences of the Fernando Pessoa University, 4249-004, Porto, Portugal; Research Department of the Portuguese League Against Cancer-Regional Nucleus of the North (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), 4200-177, Porto, Portugal. Electronic address: ruimedei@ipoporto.min-saude.pt.Portugal
- 文献类型
- 综述
- 期刊
- Critical reviews in oncology/hematology2021 Dec
- 原文标识
- PubMed 34801696 · DOI 10.1016/j.critrevonc.2021.103541